

Ministry of Health

## Drugs and Devices Division

Drug Submission Status

Report for May 2021

### Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Sanis Health Inc.	Eletriptan	Relpax	ELETRIPTAN HYDROBROMIDE	20 mg	tablet	02511266
Sanis Health Inc.	Eletriptan	Relpax	ELETRIPTAN HYDROBROMIDE	40 mg	tablet	02511274
Angita Pharma Inc.	AG-Rizatriptan ODT	Maxalt RPD	RIZATRIPTAN BENZOATE	10 mg	orally disintegrating tablet	02492490
Sandoz Canada Inc.	Sandoz Pirfenidone Tablets	Esbriet	PIRFENIDONE	267 mg	FC tablet	02488507
Sandoz Canada Inc.	Sandoz Pirfenidone Tablets	Esbriet	PIRFENIDONE	801 mg	FC tablet	02488515
Dr. Reddy's Laboratories	Reddy-Dasatinib	Sprycel	DASATINIB	20 mg	tablet	02514737

Dr. Reddy's Laboratories	Reddy-Dasatinib	Sprycel	DASATINIB	50 mg	tablet	02514745
Dr. Reddy's Laboratories	Reddy-Dasatinib	Sprycel	DASATINIB	70 mg	tablet	02514753
Dr. Reddy's Laboratories	Reddy-Dasatinib	Sprycel	DASATINIB	80 mg	tablet	02514761
Dr. Reddy's Laboratories	Reddy-Dasatinib	Sprycel	DASATINIB	100 mg	tablet	02514788
Dr. Reddy's Laboratories	Reddy-Dasatinib	Sprycel	DASATINIB	140 mg	tablet	02514796